NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-DA-17-044 from the NIH Guide for Grants and Contracts
Notice NOT-MH-17-033 from the NIH Guide for Grants and Contracts
Notice NOT-DA-17-043 from the NIH Guide for Grants and Contracts
Notice NOT-RM-17-030 from the NIH Guide for Grants and Contracts
Notice NOT-EB-17-004 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-318 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated early phase clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product.
Funding Opportunity PAR-17-319 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated early phase clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product.
Notice NOT-OD-17-072 from the NIH Guide for Grants and Contracts
Notice NOT-AI-17-032 from the NIH Guide for Grants and Contracts
Notice NOT-DE-17-011 from the NIH Guide for Grants and Contracts
Notice NOT-NS-17-031 from the NIH Guide for Grants and Contracts
Notice NOT-NS-17-030 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-521 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-520 from the NIH Guide for Grants and Contracts
Notice NOT-FD-18-001 from the NIH Guide for Grants and Contracts
Notice NOT-OD-17-076 from the NIH Guide for Grants and Contracts
Notice NOT-AR-17-017 from the NIH Guide for Grants and Contracts
Notice NOT-TR-17-018 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-17-317 from the NIH Guide for Grants and Contracts. These administrative supplements provide funds to awarded P30 Environmental Health Sciences Core Centers to enhance interactions across Centers to address emerging issues and to advance research, translation, and community engagement.
Funding Opportunity RFA-DA-18-011 from the NIH Guide for Grants and Contracts. The National Institute on Drug Abuse supported a number of HIV/AIDS cohorts among substance abusing populations. These cohorts address emerging and high priority research on HIV/AIDS. These longitudinal cohorts serve as a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV infection, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigator-initiated research. Accomplishments by the NIDA-funded cohorts have been highly significant. Four of these cohorts (see below) will be terminated within a year if continued support is not provided. Therefore, the purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to support the maintenance and expansion of these NIDA-funded cohorts to continue to address new emerging and/or high priority research on multidisciplinary aspects of HIV/AIDS and substance abuse. This FOA will provide continued support for recruiting and retaining participants in the cohort(s) to provide insight into the changing demographics of the HIV epidemic among this high risk population in the United States (U.S.). This FOA will also continue to provide a strong resource platform for current and future collaborative efforts with other investigators to address new and emerging questions related to HIV infection, prevention, and/or treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigatorinitiated research goals.